½ÃÀ庸°í¼­
»óǰÄÚµå
1677950

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Á¦Ç° À¯Çüº°, Åõ¿© ¹æ¹ýº°, °ø±Þ¿øº°, »óź°, Á¦Ç°º°, Ä¡·á¹ýº°, À¯Åë ä³Îº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)

Heparin Market Size, Share, and Growth Analysis, By Product Type, By Mode of Administration, By Source, By Ingredient, By Availability, By Treatment, By Distribution Channel, By Application, By End User, By Region - Industry Forecast 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 219 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÇìÆÄ¸° ¼¼°è ½ÃÀå ±Ô¸ð´Â 2023³â 71¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â 74¾ï 1,000¸¸ ´Þ·¯¿¡¼­ 2032³â 103¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ̸ç, ¿¹Ãø ±â°£(2025-2032³â) µ¿¾È 4.3%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÇìÆÄ¸° ½ÃÀåÀº ÁÖ·Î ½ÉÇ÷°üÁúȯÀÇ À¯º´·ü Áõ°¡, Àα¸ °í·ÉÈ­, ¿Ü°ú ¼ö¼úÀÇ ±ÞÁõ¿¡ ÈûÀÔ¾î ÇコÄÉ¾î ¹× Á¦¾à ºÐ¾ßÀÇ Áß¿äÇÑ ±¸¼º¿ä¼Ò·Î ÀÚ¸® Àâ¾Ò½À´Ï´Ù. »ýȰ½À°üº´ÀÇ Áõ°¡·Î ÀÎÇØ Ç×ÀÀ°íÁ¦, ƯÈ÷ ÀÌ·¯ÇÑ ÁúȯÀÇ °ü¸®¿¡ ÇʼöÀûÀÎ ÇìÆÄ¸°¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÔ¿øÀ² Áõ°¡¿Í ¿Ü°úÀû °³ÀÔ°ú °°Àº ¿äÀÎÀÌ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ ´ç±¹ÀÇ °¨½Ã, ½ÃÀå °æÀï, ÇìÆÄ¸° À¯¹ß¼º Ç÷¼ÒÆÇ °¨¼ÒÁõ°ú °°Àº ÇÕº´Áõ¿¡ µû¸¥ À§Çè µîÀÇ ¹®Á¦°¡ Å« Àå¾Ö¹°ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ±×·³¿¡µµ ºÒ±¸ÇÏ°í ¹ÙÀÌ¿À½Ã¹Ð·¯ °³¹ß, ¾à¹°Àü´Þ ¸ÞÄ¿´ÏÁòÀÇ ¹ßÀü, ½ÅÈï±¹ ½ÃÀåÀÇ ¼ºÀå µîÀ¸·Î ÀÎÇÑ ±âȸ·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀÌ ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

¼Ò°³

  • Á¶»ç ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀå °¡Á¤°ú Á¦ÇÑ

ÁÖ¿ä ¿ä¾à

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀΰú ±âȸ
    • ¼ºÀå ¾ïÁ¦¿äÀΰú °úÁ¦
  • Porters ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • Çٽɼº°ø¿äÀÎ
  • °æÀï Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå »ýŰè
  • ½ÃÀå ¸Å·Â Áö¼ö(2024³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • »ç·Ê ¿¬±¸
  • ±â¼úÀÇ Áøº¸

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : Á¦Ç° À¯Çüº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ¹ÌºÐÇÒ ÇìÆÄ¸°
  • ÀúºÐÀÚ·® ÇìÆÄ¸°(LMWH)
  • ÃÊÀúºÐÀÚ·® ÇìÆÄ¸°(ULMWH)

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : Åõ¿© ¹æ¹ýº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • °æ±¸ Åõ¿©
  • ºñ°æ±¸ Åõ¿©

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : °ø±Þ¿øº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ¼Ò
  • µÅÁö

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : ¼ººÐº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ³ªÆ®·ý
  • Ä®½·
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : »óź° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ¿ø½Ã
  • °¡°ø

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : Ä¡·áº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ½ÉºÎÁ¤¸ÆÇ÷ÀüÁõ
  • Æó»öÀüÁõ
  • µ¿¸Æ Ç÷Àü»öÀüÁõ
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : Ä¡·á¿ªº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ½ÉÇ÷°ü
  • È£Èí±â
  • Á¾¾çÇÐ
  • ½ÅÀåÇÐ
  • ÁßÃ߽Űæ°è
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : Èûº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • 10-1000´ÜÀ§
  • 100-5000´ÜÀ§
  • 5000-25000´ÜÀ§
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : À¯Çüº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • Á¦³×¸¯
  • ºê·£µå

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : ¿ë±âº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • º¸Æ²
  • ¹é
  • ¹ÙÀ̾Ë
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : Æ÷À庰 & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • À¯¸®
  • ÇÃ¶ó½ºÆ½

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : À¯Åë ä³Îº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹ ¹× µå·°½ºÅä¾î
  • ¿Â¶óÀÎ ¾à±¹
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : ¿ëµµº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ¼ö¼ú Àü ½Ã¼ú
  • ¼ö¼ú ÈÄ ½Ã¼ú
  • ½ÅÀå Åõ¼®
  • Áø´Ü Å×½ºÆ®
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • º´¿ø
  • Ŭ¸®´Ð
  • ÀçÅà Äɾî
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ±âŸ

ÇìÆÄ¸° ½ÃÀå ±Ô¸ð : Áö¿ªº° & CAGR(2025-2032³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • »óÀ§ 5°³»çÀÇ ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤¿ëÇÑ Àü·«
  • ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • ±â¾÷ »ó¼¼
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ±â¾÷ ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâ Àü³âºñ ºñ±³(2022-2024³â)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Opocrin S.p.A.(Italy)
  • Baxter International Inc.(U.S.)
  • Pfizer Inc.(U.S.)
  • Bioiberica S.A.U.(Spain)
  • Fresenius SE & Co. KGaA(Germany)
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.(China)
  • B. Braun SE(Germany)
  • Dr. Reddy's Laboratories Ltd.(India)
  • LEO Pharma A/S(Denmark)
  • Aspen Holdings(South Africa)
  • Gland Pharma(India)
  • Hikma Pharmaceuticals(United Kingdom)
  • Techdow USA(U.S.)
  • Viatris Inc.(U.S.)
  • Biological E. Limited(India)
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd.(China)
  • Faran Shimi Pharmaceutical Company(Iran)
  • Octapharma AG(Switzerland)
  • Kamada Ltd.(Israel)

°á·Ð°ú Á¦¾È

ksm 25.04.18

Global Heparin Market size was valued at USD 7.1 billion in 2023 and is poised to grow from USD 7.41 billion in 2024 to USD 10.37 billion by 2032, growing at a CAGR of 4.3% during the forecast period (2025-2032).

The global heparin market is a critical component of the healthcare and pharmaceutical sectors, driven primarily by the increasing prevalence of cardiovascular diseases, an aging population, and a surge in surgical procedures. The rising incidence of lifestyle-related illnesses is elevating the demand for anticoagulants, particularly heparin, which is essential for managing these conditions. Factors such as higher hospitalization rates and surgical interventions further bolster market growth. However, challenges such as regulatory scrutiny, market competition, and risks associated with complications, including heparin-induced thrombocytopenia, pose significant hurdles. Nevertheless, the market is expected to thrive due to opportunities arising from the development of biosimilars, advancements in drug delivery mechanisms, and growth in emerging markets.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Heparin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Heparin Market Segments Analysis

Global Heparin Market is segmented by Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User and region. Based on Product Type, the market is segmented into Unfractionated Heparin, Low Molecular Weight Heparin (LMWH) and Ultra-Low Molecular Weight Heparin (ULMWH). Based on Mode of Administration, the market is segmented into Oral Administration and Parenteral Administration. Based on Source, the market is segmented into Bovine and Porcine. Based on Ingredient, the market is segmented into Sodium, Calcium and Others. Based on Availability, the market is segmented into Raw and Processed. Based on Treatment, the market is segmented into Deep Vein Thrombosis, Pulmonary Embolism, Arterial Thromboembolism and Others. Based on Therapeutics, the market is segmented into Cardiovascular, Respiratory, Oncology, Nephrology, CNS and Others. Based on Strength, the market is segmented into 10 -1000 Unit, 1000 -5000 Unit, 5000- 25000 Unit and Others. Based on Type, the market is segmented into Generics and Brands. Based on Container, the market is segmented into Bottles, Bags, Vials and Others. Based on Packaging, the market is segmented into Glass and Plastic. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Store, Online Pharmacy and Others. Based on Application, the market is segmented into Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Diagnostic Tests and Others. Based on End User, the market is segmented into Hospitals, Clinics, Homecare, Ambulatory Surgical Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Heparin Market

The global heparin market is primarily driven by the prevalence of cardiovascular diseases, which remain a leading cause of death and illness worldwide. Conditions such as heart attacks, atrial fibrillation, and strokes significantly heighten the risk of thromboembolic complications, thereby boosting the need for anticoagulants like heparin. Additionally, the rising incidence of pulmonary embolism (PE) and deep vein thrombosis (DVT) further fuels the demand for heparin, as it is widely recognized as the standard treatment for these conditions. As a result, the growing focus on cardiovascular health and related disorders continues to propel the heparin market forward.

Restraints in the Global Heparin Market

The global heparin market faces significant restraints primarily due to the severe side effects associated with heparin therapy, particularly the risk of bleeding, which can lead to patient hesitance and concerns among healthcare providers regarding its use. Additionally, conditions such as Heparin-Induced Thrombocytopenia (HIT) can result in serious complications, thereby undermining the confidence in and safety of heparin treatment. Furthermore, the requirement for continuous monitoring of activated partial thromboplastin time (aPTT) with unfractionated heparin to prevent adverse effects and ensure therapeutic efficacy complicates treatment regimens, particularly in outpatient settings, thereby limiting its wide-scale adoption.

Market Trends of the Global Heparin Market

The global heparin market is experiencing a significant shift with a heavy focus on biosimilars, driven by the expiry of patents for original heparin products. This trend is particularly pronounced in Europe and North America, where healthcare providers seek cost-effective alternatives that maintain safety and efficacy. The rise in biosimilars allows for reduced treatment costs, further enhancing patient access to necessary anticoagulant therapies. As regulatory bodies continue to streamline the approval process for these biosimilars, the heparin market is poised for substantial growth, reflecting a broader move towards cost-efficient healthcare solutions while prioritizing patient outcomes.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Regulatory Landscape
  • Case Studies
  • Technological Advancement

Global Heparin Market Size by Product Type & CAGR (2025-2032)

  • Market Overview
  • Unfractionated Heparin
  • Low Molecular Weight Heparin (LMWH)
  • Ultra-Low Molecular Weight Heparin (ULMWH)

Global Heparin Market Size by Mode of Administration & CAGR (2025-2032)

  • Market Overview
  • Oral Administration
  • Parenteral Administration

Global Heparin Market Size by Source & CAGR (2025-2032)

  • Market Overview
  • Bovine
  • Porcine

Global Heparin Market Size by Ingredient & CAGR (2025-2032)

  • Market Overview
  • Sodium
  • Calcium
  • Others

Global Heparin Market Size by Availability & CAGR (2025-2032)

  • Market Overview
  • Raw
  • Processed

Global Heparin Market Size by Treatment & CAGR (2025-2032)

  • Market Overview
  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Arterial Thromboembolism
  • Others

Global Heparin Market Size by Therapeutics & CAGR (2025-2032)

  • Market Overview
  • Cardiovascular
  • Respiratory
  • Oncology
  • Nephrology
  • CNS
  • Others

Global Heparin Market Size by Strength & CAGR (2025-2032)

  • Market Overview
  • 10 -1000 Unit
  • 1000 -5000 Unit
  • 5000- 25000 Unit
  • Others

Global Heparin Market Size by Type & CAGR (2025-2032)

  • Market Overview
  • Generics
  • Brands

Global Heparin Market Size by Container & CAGR (2025-2032)

  • Market Overview
  • Bottles
  • Bags
  • Vials
  • Others

Global Heparin Market Size by Packaging & CAGR (2025-2032)

  • Market Overview
  • Glass
  • Plastic

Global Heparin Market Size by Distribution Channel & CAGR (2025-2032)

  • Market Overview
  • Hospital Pharmacy
  • Retail Pharmacy and Drug Store
  • Online Pharmacy
  • Others

Global Heparin Market Size by Application & CAGR (2025-2032)

  • Market Overview
  • Pre-Surgical Procedures
  • Post-Surgical Procedures
  • Kidney Dialysis
  • Diagnostic Tests
  • Others

Global Heparin Market Size by End User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Clinics
  • Homecare
  • Ambulatory Surgical Centres
  • Others

Global Heparin Market Size & CAGR (2025-2032)

  • North America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
    • US
    • Canada
  • Europe (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product Type, Mode of Administration, Source, Ingredient, Availability, Treatment, Therapeutics, Strength, Type, Container, Packaging, Distribution Channel, Application, End User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Opocrin S.p.A. (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bioiberica S.A.U. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Fresenius SE & Co. KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hebei Changshan Biochemical Pharmaceutical Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • B. Braun SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dr. Reddy's Laboratories Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LEO Pharma A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Aspen Holdings (South Africa)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gland Pharma (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hikma Pharmaceuticals (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Techdow USA (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Viatris Inc. (U.S.)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biological E. Limited (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Faran Shimi Pharmaceutical Company (Iran)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Octapharma AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kamada Ltd. (Israel)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦